M. Juliana McElrath

Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response.

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Progress in the development of a preventive HIV-1 vaccine.

Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection.

Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity.

Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals.

Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection.

HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.

Most highly exposed seronegative men lack HIV-1-specific, IFN-gamma-secreting T cells.

Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.

Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection.

Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations.

Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion.

Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.

Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele.

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.

Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1.

Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression.

Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells.

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms.

High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.

Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.

CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression.

Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility.

Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.

Abacavir hypersensitivity reaction in primary HIV infection.

Selection on the human immunodeficiency virus type 1 proteome following primary infection.

Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection.

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection.

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.

Comprehensive epitope analysis of cross-clade Gag-specific T-cell responses in individuals with early HIV-1 infection in the US epidemic.

Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1.

Enhanced detection of human immunodeficiency virus type 1 (HIV-1) Nef-specific T cells recognizing multiple variants in early HIV-1 infection.

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.

Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination.

Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.

Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape.

A framework for assessing immunological correlates of protection in vaccine trials.

Novel cytotoxic T-lymphocyte escape mutation by a three-amino-acid insertion in the human immunodeficiency virus type 1 p6Pol and p6Gag late domain associated with drug resistance.

Setting the stage: host invasion by HIV.

Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Impaired viral entry cannot explain reduced CD4+ T cell susceptibility to HIV type 1 in certain highly exposed individuals.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Post-step modifications for research on HIV vaccines.

T cell responses generated by HIV vaccines in clinical trials.

Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells.

Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.

Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization.

Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.

Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses.

Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype.

In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques.

HIV vaccines: mosaic approach to virus diversity.

Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms.

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies.

Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.

Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the step trial.

Dynamics of viral evolution and CTL responses in HIV-1 infection.

Standing guard at the mucosa.

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.

Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles.

Association between peripheral γδ T-cell profile and disease progression in individuals infected with HIV-1 or HIV-2 in West Africa.

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1.

Host genetic polymorphisms associated with innate immune factors and HIV-1.

Protective HIV-specific CD8+ T cells evade Treg cell suppression.

HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.

A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.

Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.

Vaginal langerhans cells nonproductively transporting HIV-1 mediate infection of T cells.

Profiling immunity to HIV vaccines with systems biology.

Genomewide association study for determinants of HIV-1 acquisition and viral set point in HIV-1 serodiscordant couples with quantified virus exposure.

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.

Vpu Mediates Depletion of Interferon Regulatory Factor 3 during HIV Infection by a Lysosome-Dependent Mechanism.

Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells.

Vpu-Deficient HIV Strains Stimulate Innate Immune Signaling Responses in Target Cells.

Two new monoclonal antibodies for biochemical and flow cytometric analyses of human interferon regulatory factor-3 activation, turnover, and depletion.

Is an HIV vaccine possible?

A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity.

Quantifying Ongoing HIV-1 Exposure in HIV-1-Serodiscordant Couples to Identify Individuals With Potential Host Resistance to HIV-1.

MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.